Chinese patients are reportedly more sensitive than Caucasians to the anticoagulant effect of warfarin. We examined warfarin dose requirements and their determinants in 151 Chinese out-patients on stable maintenance dose of warfarin with international normalized ratio of 2 to 2.5. Mean daily warfarin requirement was 3.3 + 1 . 4 mg, much lower than reported doses in Caucasian patients. The most important determinant was age ( r = -0 . 4 3 , p< 0.001), with progressively lower warfarin requirement with increasing age (p = 0.0001). There was a weaker association with body weight (r = 0.20, p = 0.01). Patients with chronic rheumatic heart disease tended to require a smaller dose than those with heart valve replacements (2.94 + 1.24 vs. 3.69 + 1.42 mg, p<0.01). We confirm that Chinese patients require a smaller dose of warfarin for the same degree of anticoagulation. Age is the most important factor affecting dose requirement, although body weight and underlying disease also play a role.
Introduction
Chinese patients appear to be more sensitive to the anticoagulant effect of warfarin than Caucasian patients are. In an international collaborative survey of dosages and control of oral anticoagulants, 1 Hong
Kong physicians were found to prescribe a much lower mean dose (2.45 mg daily) than the rest of the world (4.0-8.76 mg daily), although the intensity of the anticoagulation was comparable. In a subsequent study of 33 Chinese patients with deep vein thrombosis and/or pulmonary embolism, 2 the mean dosage required to maintain an international normalized ratio (INR) of 2.0-2.5 was found to be 3.0 mg daily. In 458 Chinese patients with prosthetic heart valves and an INR of 2.0-3.0, 3 the mean daily dose was 3.1 mg. In contrast, the maintenance dose to keep INR at target range of 1.8-2.5 in 228 Caucasian patients with coronary, valvular, thromboembolic or peripheral vascular diseases was nearly double at 6.1 mg. 4 The correct dosing of warfarin is of obvious importance in relation to drug efficacy and safety. It is useful in clinical practice to determine if significant differences exist in warfarin sensitivity between different ethnic groups. In Caucasian subjects, the age of the patient rather than body weight is an important determinant of warfarin requirements. 4 Similar findings have been reported from a small study of Chinese patients with deep vein thrombosis and/or pulmonary embolism. 2 However, whether the warfarin requirement and its determinants may differ in Chinese patients with cardiac conditions are not known. It should be remembered that the latter group accounts for the majority of patients receiving long-term warfarin. Chinese ethnicity is found in most parts of the world. The main objective of the present study was to define the usual warfarin requirements and their determinants in Chinese patients with different indications for anticoagulation.
Methods
Between July and December 1994, all Chinese patients receiving warfarin who had attended our medical out-patient clinics at the Prince of Wales Hospital were considered for inclusion in the study. They were mostly identified from the registry of requests for INR and reviewed by a single investigator. They were receiving a stable maintenance dose of warfarin for at least one month prior to the study day. The warfarin dose was considered to have stabilized if it had remained unchanged in two consecutive visits with an INR of 2.0-2.5. Exclusion criteria were uncontrolled heart failure (New York Heart Association functional class III and IV), liver disease, thyrotoxicosis, hypothyroidism and concurrent drugs that are known to interact with warfarin. 5 ' 6 Patients with clinically stable tricuspid regurgitation but normal liver function tests were not excluded from the study. Case notes were reviewed, and the following information noted: sex, age, body weight, indication and duration of warfarin therapy, the stabilized dose of warfarin, concomitant medical conditions and medications, cardiac status and relevant laboratory data.
All data were expressed as means+ SD. The significance of the difference between variables was assessed using Student's t test or analysis of variance (ANOVA) where appropriate. The relationship between variables was evaluated using linear regression analysis. The relative importance of various factors as the determinants of warfarin requirements was evaluated by multiple regression analysis. p < 0 . 0 5 was considered statistically significant.
Results
A total of 151 Chinese patients (61 men, 90 women) were studied. Their mean age was 52.0 + 12.1 years (range 27-80) and body weight was 55.8 + 10.8 kg. As expected, the men were heavier than the women (61.5 vs. 52.1 kg, p<0.0001). The main indications for warfarin therapy included heart valve replacements (43%), chronic rheumatic heart disease (37%), deep vein thrombosis (10%) and atrial fibrillation (6%). The duration of warfarin therapy was 57 + 43 months, and the INR at the time of the study was 2.25 + 0.17.
The mean warfarin requirement in the 151 patients was 3.3 + 1.4 mg (range 1.25-7.5 mg). Men did not differ from women in their warfarin requirements (3.5 vs. 3.2 mg, p = 0.25). As shown in Figure 1 , 70% of patients required 2 -4 mg daily, 8 1 % of patients 2-5 mg daily.
There was a negative correlation between the age of patient and the warfarin requirement (r= -0.43, p<0.001). The warfarin requirements fell with increasing age (ANOVA p = 0.0001). In patients aged 31-40 years the dose (3.99 mg) was about twice as much as that in patients aged over 70 years (2.25 mg) (Figures 2 and 3 ).
There was a positive but weaker relationship between the body weight of the patient and the warfarin requirement (r = 0.20, p = 0.01) (Figure 4) .
Patients with heart valve replacements required a bigger warfarin dose (3.69 + 1.42 mg) than those with chronic rheumatic heart disease (2.94 + 1.24 mg) and deep vein thrombosis or other conditions (3.17 ± 1.26 mg) ( Table 1) .
Using multiple regression analysis, the most important determinant of warfarin requirement in the total study population was the age of the patient (p<0.00005) ( Table 2 ). Other less significant factors included indications for warfarin therapy (p = 0.008) and body weight (p = 0.04). The gender of the patient, the INR at the time of the study and duration of warfarin therapy were not significant.
Discussion
Although there have been suggestions that Chinese patients are more sensitive than Caucasians to the anticoagulant effect of warfarin, 1 little is known about the factors affecting their maintenance dose.
The two previous studies of the warfarin requirement 2 ' 3 and/or its determinants 2 in Chinese patients were either small, 2 restricted to one diagnostic group (deep vein thrombosis and/or pulmonary embolism 2 or heart valve replacements 3 ) or were confounded by inclusion of patients with heart failure, liver dysfunction and drug interactions. 3 We have recruited patients from different diagnostic groups, but excluded those with confounding factors that may affect the warfarin requirement.
This study confirms that the mean warfarin requirement in Chinese patients is around 3 mg 2 ' 3 and that the majority of patients (81%) require 2-5 mg daily to achieve an INR of 2.0-2.5. In contrast, patients from the UK 4 ' 7 " 10 and US 15 generally require 4 -6 mg daily to achieve an INR of 1.8-3.0 (Tables 3 and 4) . Again, all but one 4 of these studies failed to exclude patients with liver disease or other confounding variables.
At present, it is unknown why Chinese are more sensitive to the anticoagulant effect of warfarin than Caucasians. Both pharmacokinetic and pharmacodynamic factors may possibly contribute to the observed phenomenon. Several drugs show differences either in metabolism or in the incidence of side-effects between Chinese and other ethnic groups. For example, propranolol is metabolized faster but has greater beta-blocking effect in US Chinese compared with Whites. On the other hand, the incidence of ACE-inhibitor-induced cough is much higher in Chinese than in Caucasians in New Zealand and in other Western reports. 12 ' 13 The use of recombinant tissue plasminogen activator in acute myocardial infarction in Hong Kong Chinese had a higher incidence of coagulopathy and bleeding complications compared to Caucasian reports. 14 However, pharmacodynamic factors are likely to be more important than pharmacokinetic factors, as no difference in warfarin binding to plasma albumin has been found between healthy Chinese and Caucasian subjects. 16 ' 17 Warfarin reversibly binds with and inhibits vitamin K epoxide reductase and vitamin K quinone reductase, enzymes responsible for converting the biologically inactive vitamin K epoxide to active vitamin K hydroquinone. 5 Thus, warfarin inhibits the final activation step in the synthesis of vitamin-K-dependent clotting factors. It is possible that in Chinese patients, these enzymes are intrinsically more sensitive to the action of warfarin. In our study, the mean body weight is about 11 kg lower than the Caucasian population. 8 However, by multiple regression, this only explains 0.2 mg of the lower mean dose required. The observed difference in warfarin requirement (1-3 mg) cannot simply be explained by lower body weight in the Chinese. Changes in dietary vitamin K intake can affect the optimal anticoagulation control 18 and even cause life-threatening complications. 19 However, such patients usually present with instability of anticoagulation control, which should be excluded by the inclusion criteria in our study. The usual dietary vitamin K intake in Chinese is about 300 mg/kg which well exceeds the recommended dietary requirement of vitamin K of 1 mg/kg body weight in Caucasian population. Therefore it is unlikely that dietary vitamin K intake is significant in the difference in warfarin requirement observed.
We have also confirmed that the age of the patient is the most important determinant of warfarin require-, ment in Chinese patients. This agrees with findings in patients in the UK 4 and the US 10 (Table 4 ). An age-related decline in the dose of warfarin required to produce the same anticoagulant effect has also been reported. 20 ' 21 However, in Caucasians, studies with single doses of warfarin did not show appreciable differences in warfarin pharmacokinetics (plasma half-life, apparent volume of distribution, plasma clearance, plasma protein binding or warfarin levels) between younger and older patients. 20 For the same plasma warfarin concentrations, there was greater inhibition of vitamin-K-dependent clotting factor synthesis in the elderly, but no difference in the rate of clotting factor degradation. 20 Studies of warfarin pharmacokinetics and pharmacodynamics at steady-state showed a lack of relationship between free plasma clearance and the age of the patient, suggesting that decreasing ability to metabolize racemic warfarin is not responsible for age-related increases in warfarin sensitivity. 21 There was no difference in the serum concentrations of enantiomers and the clearance of S-warfarin at steady-state between young and elderly patients, but the clearance of the pharmacologically less active R-warfarin was lower in older patients. 22 The observation that older patients had a lower dose requirement and the lack of alternation in the steady-state pharmacokinetic parameters of warfarin is consistent with the age-related increase in the intrinsic sensitivity to warfarin. It has been speculated that the increase in sensitivity may be a result of the fall in functional liver mass 23 and a change in the activity of vitamin DVT, deep vein thrombosis; HVR, heart valve replacement; CRHD, rheumatic heart disease; IHD, ischaemic heart disease; AD, arterial disease; AF, atrial fibrillation; TIA, transient ischaemic attack; CVA, cerebrovascular accident. We found that warfarin requirement also differed in relation to the indications for anticoagulation even after adjustment for other determinants (Table 4 ). This is in keeping with the findings of others. 15 Patients with heart valve replacement tended to require a bigger maintenance dose than those with chronic rheumatic heart disease and other conditions. One possible explanation is that after surgery, fewer patients in the heart valve replacement group had liver dysfunction secondary to mild or subclinical heart failure or tricuspid regurgitation. Our study has important implications for the care of Chinese patients who require long-term warfarin therapy. The average maintenance dose is considerably lower in Chinese patients and the anticoagulant response is exaggerated in older patients. Intensity of anticoagulation is the most important predictor of bleeding in patients treated with warfarin. 22 ' 23 Patient age also appears to be an independent risk factor for the development of bleeding complications. 25 ' 26 It should also be remembered that gastrointestinal haemorrhage from peptic ulcers is very common in Chinese patients. 27 ' 28 Bleeding from the gastrointestinal tract is expected to be more severe during warfarin use. Our results emphasize the smaller warfarin requirements in Chinese patients, which should be noted in prescribing warfarin to the Chinese.
